Skip subpage navigation
Influenza is a world-wide contagious respiratory illness caused by influenza viruses. The virus is spread through close contact with an infected person. The incubation period is commonly 2 days, but ranges from 1 to 4 days. Due to its short incubation period, influenza outbreaks may escalate very quickly, especially in highly susceptible populations. Influenza illness is characterized by the abrupt start of fever, sore throat, headache, myalgia, non-productive cough and extreme fatigue with major symptoms lasting an average of 2 to 3 days. Fever usually ranges between 100° and 104°F. Illness typically improves within a week, but cough and malaise may persist for 2 or more weeks. The most common complications of influenza is pneumonia, but may include exacerbation of underlying chronic pulmonary and cardiopulmonary diseases, such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.
There are many brands of Northern Hemisphere influenza vaccines available. Recently, one brand of vaccine for Southern Hemisphere influenza vaccine became available in the United States.
Northern Hemisphere influenza vaccine will be administered to all assigned to an area designated as a Northern Hemisphere influenza zone between October and April. Southern Hemisphere influenza vaccine will be administered to all permanently or temporarily assigned to an area designated as a Southern Hemisphere influenza zone between April and October. Northern and Southern Hemisphere-designated countries will be identified by the Defense Health Agency or the Type/Combatant Command to which an individual may be permanently or temporarily assigned. Personnel traveling to either the Northern or Southern Hemisphere during that hemisphere’s influenza season should be vaccinated at least two weeks prior to entry into the region. Northern and Southern Hemisphere influenza vaccines should be separated by at least 28 days.
You will find below all of the resources you will need for the Southern Hemisphere influenza season. More will be added as they are published or released.
Policy |
Date |
Defense Health Agency-Procedural Instruction 6025.52: Guidance for the DOD Influenza Vaccination Program |
June 4, 2024 |
Information Paper |
Date |
Influenza Infection and Influenza Vaccines
|
Aug. 9, 2024 |
Vaccine Information Statements |
Date |
Live, Intranasal Flu Vaccine
|
Aug. 6, 2021 |
Inactivated or Recombinant (injectable) Flu Vaccine
|
Aug. 6, 2021 |
Screening Form (Right-click and save this document to your desktop in order to fill it out and add digital signature) |
Date |
DHA Form 116: Pediatric and Adult Influenza Screening and Immunization Documentation
|
August 2024 |
Package Inserts |
Date |
Afluria Southern Hemisphere
|
March 1, 2024
|
Fluzone Southern Hemisphere
|
Feb. 14, 2024
|
Standing Orders |
Date |
Influenza Vaccine (Pediatric)
|
Aug. 9, 2024
|
Influenza Vaccine (Adults)
|
Aug. 9, 2024
|
Competency Assessment |
Date |
Initial/Annual Competency Assessment Checklist: Influenza Vaccine Administration
|
Aug. 9, 2024 |
Influenza Vaccine Product List |
Date |
Influenza Vaccine Product List and Age Groups – United States, 2024-25 Season
|
July 24, 2024 |
You also may be interested in...
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: August 16, 2024